CNPase Mouse anti-Human, Clone: OTI3C3, Invitrogen
Mouse Monoclonal Antibody
Manufacturer: Invitrogen MA527394
DescriptionThis gene encodes a member of the Notch family. Members of this Type 1 transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple, different domain types. Notch family members play a role in a variety of developmental processes by controlling cell fate decisions. The Notch signaling network is an evolutionarily conserved intercellular signaling pathway which regulates interactions between physically adjacent cells. In Drosophilia, notch interaction with its cell-bound ligands (delta, serrate) establishes an intercellular signaling pathway that plays a key role in development. Homologues of the notch-ligands have also been identified in human, but precise interactions between these ligands and the human notch homologues remain to be determined. This protein is cleaved in the trans-Golgi network, and presented on the cell surface as a heterodimer. This protein functions as a receptor for membrane bound ligands, and may play a role in vascular, renal and hepatic development. This gene may be associated with susceptibility to schizophrenia in a small portion of cases. An alternative splice variant has been described but its biological nature has not been determined.
|PBS with 1% BSA, 50% glycerol and 0.02% sodium azide; pH 7.3|
|CNP1, 2′, 3′ cyclic nucleotide 3′ phosphohydrolase; 2′,3′-cyclic-nucleotide 3′-phosphodiesterase; CNPase|
|-20° C, Avoid Freeze/Thaw Cycles|
|Immunohistochemistry (Paraffin), Western Blot|
|Full length human recombit protein of CNP produced in HEK293T cell|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok